Truist Financial Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health (NYSE:HIMS) had its price target raised by equities research analysts at Truist Financial from $18.00 to $23.00 in a report released on Friday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price objective points to a potential downside of 3.29% from the company’s current price.

Several other equities research analysts also recently weighed in on the company. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Evercore set a $24.00 price target on Hims & Hers Health in a report on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Barclays increased their price target on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. Finally, Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $29.70.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $0.23 during mid-day trading on Friday, reaching $23.78. 5,789,593 shares of the company’s stock were exchanged, compared to its average volume of 32,364,117. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The stock has a market capitalization of $5.42 billion, a PE ratio of -264.06, a price-to-earnings-growth ratio of 21.68 and a beta of 2.43. The business’s fifty day simple moving average is $24.08 and its 200-day simple moving average is $28.13. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted $0.20 earnings per share. On average, equities research analysts expect that Hims & Hers Health will post 0.08 earnings per share for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the sale, the insider owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. This trade represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 36,922 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total value of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares of the company’s stock, valued at approximately $7,300,355.30. This trade represents a 11.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 212,807 shares of company stock worth $5,473,644. Company insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Binnacle Investments Inc acquired a new stake in Hims & Hers Health in the third quarter valued at $28,000. Silicon Valley Capital Partners acquired a new stake in Hims & Hers Health in the third quarter valued at $48,000. Flagship Harbor Advisors LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at $28,000. Bogart Wealth LLC lifted its holdings in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after acquiring an additional 283 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.